We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest market close, Novavax (NVAX - Free Report) reached $10.35, with a +1.97% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.02%. On the other hand, the Dow registered a gain of 0.38%, and the technology-centric Nasdaq increased by 0.04%.
Prior to today's trading, shares of the vaccine maker had lost 19.19% over the past month. This has lagged the Medical sector's loss of 4.19% and the S&P 500's gain of 3.77% in that time.
Analysts and investors alike will be keeping a close eye on the performance of Novavax in its upcoming earnings disclosure. The company is expected to report EPS of -$0.87, up 30.95% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $57.32 million, reflecting a 69.34% fall from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.90 per share and a revenue of $773 million, indicating changes of +83.36% and -21.42%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 12.88% higher. As of now, Novavax holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 93, this industry ranks in the top 37% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
In the latest market close, Novavax (NVAX - Free Report) reached $10.35, with a +1.97% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.02%. On the other hand, the Dow registered a gain of 0.38%, and the technology-centric Nasdaq increased by 0.04%.
Prior to today's trading, shares of the vaccine maker had lost 19.19% over the past month. This has lagged the Medical sector's loss of 4.19% and the S&P 500's gain of 3.77% in that time.
Analysts and investors alike will be keeping a close eye on the performance of Novavax in its upcoming earnings disclosure. The company is expected to report EPS of -$0.87, up 30.95% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $57.32 million, reflecting a 69.34% fall from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.90 per share and a revenue of $773 million, indicating changes of +83.36% and -21.42%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 12.88% higher. As of now, Novavax holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 93, this industry ranks in the top 37% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.